HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Can boosted atazanavir induce hyperlipotrophy?

Abstract
Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. We report the case of an HIV/HCV co-infected patient treated with atazanavir.
AuthorsP Dellamonica
JournalThe Journal of infection (J Infect) Vol. 52 Issue 6 Pg. e189-90 (Jun 2006) ISSN: 1532-2742 [Electronic] England
PMID16239035 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Oligopeptides
  • Protease Inhibitors
  • Pyridines
  • Atazanavir Sulfate
  • Bilirubin
Topics
  • Aged
  • Atazanavir Sulfate
  • Bilirubin (blood)
  • Female
  • HIV Infections (drug therapy)
  • HIV-Associated Lipodystrophy Syndrome (chemically induced)
  • Hepatitis C (drug therapy)
  • Humans
  • Oligopeptides (adverse effects, blood, therapeutic use)
  • Protease Inhibitors (adverse effects, therapeutic use)
  • Pyridines (adverse effects, blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: